Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia
| Autor: | Michael A. Quinn, Andrew McKenzie, L. Perrin, Juliet Martin, Olivia J. White, Darryl W. Maher, Ngaire Wendt, Ian H. Frazer, James L. Nicklin, Stirling John Edwards, Susan V. Mitchell, Martin J. Pearse, Vivienne O'Connor, Peng Ng, Russell L. Basser, Jayne M Crowley, Jeffrey Tan |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Cellular immunity Adolescent viruses medicine.medical_treatment Papillomavirus E7 Proteins Recombinant Fusion Proteins Cervical intraepithelial neoplasia Cancer Vaccines Adjuvants Immunologic Medicine Humans Cervix Papillomaviridae Phospholipids Cervical cancer General Veterinary General Immunology and Microbiology business.industry Immunogenicity Papillomavirus Infections Public Health Environmental and Occupational Health virus diseases Immunotherapy Oncogene Proteins Viral Middle Aged Saponins medicine.disease Uterine Cervical Dysplasia female genital diseases and pregnancy complications Repressor Proteins Drug Combinations Infectious Diseases medicine.anatomical_structure Cholesterol Delayed hypersensitivity Immunology Molecular Medicine Female business Adjuvant |
| Zdroj: | Vaccine. 23(2) |
| ISSN: | 0264-410X |
| Popis: | Purpose: Persistent infection of cervical epithelium with high risk human papillomavirus (HPV) results in cervical intraepithelial neoplasia (CIN) from which squamous cancer of the cervix can arise. A study was undertaken to evaluate the safety and immunogenicity of an HPV 16 immunotherapeutic consisting of a mixture of HPV16 E6E7 fusion protein and ISCOMATRIX(TM) adjuvant (HPV16 Immunotherapeutic) for patients with CIN. Experimental design: Patients with CIN (n = 3 1) were recruited to a randomised blinded placebo controlled dose ranging study of immunotherapy. Results: Immunotherapy was well tolerated. Immunised subjects developed HPV16 E6E7 specific immunity. Antibody, delayed type hypersensitivity, in vitro cytokine release, and CD8 T cell responses to E6 and E7 proteins were each significantly greater in the immunised subjects than in placebo recipients. Loss of HPV16 DNA from the cervix was observed in some vaccine and placebo recipients. Conclusions : The HPV16 Immunotherapeutic comprising HPV16E6E7 fusion protein and ISCOMATRIX(TM) adjuvant is safe and induces vaccine antigen specific cell mediated immunity. (C) 2004 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect